| Cusi, Kenneth |
NCT03459079: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 2 | 128 | US | Lanifibranor, IVA 337, Placebo | University of Florida, Inventiva Pharma | Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | 04/23 | 06/23 | | |
|
|
|
NCT04501406: Low-Dose Pioglitazone in Patients With NASH (AIM 2) |
|
|
| Recruiting | 2 | 166 | US | Pioglitazone, Actos, Placebo | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis | 08/27 | 08/27 | | |
| Completed | N/A | 197 | US | Bariatric Surgery Candidates, Non surgical/Community volunteers | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes, Weightloss | 11/22 | 11/22 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Mortensen, Eric M |
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 |
|
|
| Terminated | 2 | 41 | US | Placebo, Dipyridamole Tablets, Persantine | UConn Health | COVID-19 Pneumonia, Vascular Complications | 03/22 | 04/22 | | |
| Restrepo, Marcos I |
| No trials found |
| Cunningham, Sue A |
| No trials found |
